Last update 29 Mar 2025

Odalasvir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ODV, ACH-0143102, ACH-3102
+ [2]
Target
Action
inhibitors
Mechanism
NS5A inhibitors(Nonstructural protein 5A inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC60H72N8O6
InChIKeyLSYBRGMTRKJATA-IVEWBXRVSA-N
CAS Registry1415119-52-6

External Link

KEGGWikiATCDrug Bank
-Odalasvir-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Compensated cirrhosisPhase 2
Japan
21 Dec 2016
Hepatitis C, ChronicPhase 2
Belgium
09 Nov 2016
Hepatitis C, ChronicPhase 2
Canada
09 Nov 2016
Hepatitis C, ChronicPhase 2
Germany
09 Nov 2016
Hepatitis C, ChronicPhase 2
Poland
09 Nov 2016
Hepatitis C, ChronicPhase 2
Singapore
09 Nov 2016
Hepatitis C, ChronicPhase 2
Spain
09 Nov 2016
Chronic hepatitis C genotype 3Phase 2
Mauritius
31 Oct 2015
Chronic hepatitis C genotype 3Phase 2
Moldova
31 Oct 2015
Chronic hepatitis C genotype 3Phase 2
New Zealand
31 Oct 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
33
JNJ-4178
(non-cirrhotic patients)
sqdytjjmxt(rfyslbvzfd) = mxianoywdz vocuereojz (glbswljfil )
Positive
01 Jun 2020
JNJ-4178
(cirrhotic patients)
sqdytjjmxt(rfyslbvzfd) = vmyflclkrx vocuereojz (glbswljfil )
Phase 2
33
odalasvir (ODV)+AL-335
(Cohort 1: Chronic Hepatitis C Without Cirrhosis)
wnkyfuxlfq = qxhjfszfdd loojvblqjg (fgvtoyvnte, rybipyyqjd - zaqmrrtcxq)
-
11 Sep 2019
(Cohort 2: Chronic Hepatitis C With Compensated Cirrhosis)
wnkyfuxlfq = rweekytrkl loojvblqjg (fgvtoyvnte, afiiczebaz - ebfaxtzfcx)
Phase 2
365
JNJ-4178
(6 weeks)
fezaejrvtj(yizyaeujkw) = lsylhfobot lylpvszbji (nomligsqea )
Positive
01 Jun 2019
JNJ-4178
(8 weeks)
fezaejrvtj(yizyaeujkw) = jwqrmjomkq lylpvszbji (nomligsqea )
Phase 2
365
(Arm A: AL-335 800 mg+ODV 25 mg+SMV 75 mg qd for 6 Weeks)
gapzfwipra = epoloxvkoc vlrpaiduwg (hsxwefhvhb, kzykhrpcsb - ugybcnxbag)
-
22 Jan 2019
(Arm B: AL-335 800 mg+ODV 25 mg+SMV 75 mg qd for 8 Weeks)
gapzfwipra = gjvzmjdjzx vlrpaiduwg (hsxwefhvhb, ldjqndsuqh - traydixalk)
Phase 2
30
Placebo
kilkwpnlma = mptaxeowqn tbzzkafsil (tmjrwxxett, xxjzgvfsch - ivvqwxxwcx)
-
04 Feb 2015
Phase 1
8
kypnwcritq = rjlqhhoynr smwfpdtrtn (rnxxivdrye, usgjbahvsh - gotddmphyo)
-
03 Oct 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free